COMMUNIQUÉS West-GlobeNewswire

Southern California Clinic uses MedMatrix AI Market Expander to Launch Opening of New Clinic Locations
12/03/2024
VANCOUVER, British Columbia, March 12, 2024 (GLOBE NEWSWIRE) -- MedBright AI Investments Inc. (the “Company” or “MedBright”) (CSE:MBAI, OTCQB:MBAIF, FSE:1V7) today announced that Dermatology Institute & Skin Care [...]
Pliant Therapeutics Announces Accelerated Bexotegrast Development Plan for the Treatment of Idiopathic Pulmonary Fibrosis
12/03/2024
Acceptance by European Union and other global health authorities of the pivotal, adaptive Phase 2b/3 trial will significantly shorten bexotegrast’s time to Phase 3 data Upsized Oxford Finance debt facility extends cash [...]
CorMedix Inc. Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update
12/03/2024
Conference Call Scheduled for Today at 8:30 a.m. Eastern Time BERKELEY HEIGHTS, N.J., March 12, 2024 (GLOBE NEWSWIRE) -- CorMedix Inc. (Nasdaq: CRMD), a biopharmaceutical company focused on developing and [...]
Bioventus Announces Fourth Quarter and Full Year 2023 Financial Results
12/03/2024
Accelerated fourth quarter sales growth to 7.6% , organic growth* of 14.3% Appointed Rob Claypoole as President and Chief Executive Officer, bringing more than 20 years of leadership experience in the global medical [...]
Mendus provides business update and outlook for vididencel program
12/03/2024
Press Release Stockholm, Sweden, March 12, 2024 ADVANCE II Phase 2 trial data provide basis for late-stage development of lead product vididencel in acute myeloid leukemia Registration trial preparations are ongoing, [...]
Vidac Pharma secures approval for next phase of clinical study of lead asset in Cutaneous T-Cell Lymphoma
12/03/2024
London (UK), March 12, 2024 (07:30 CET) – Vidac Pharma Holdings Plc. (Hamburg and Stuttgart: T9G; ISIN:GB00BM9XQ619; WKN: A3DTUQ), a clinical-stage oncology biopharmaceutical company pioneering a novel class of cancer [...]
Azafaros announces completion of 12-week Phase 2 RAINBOW study evaluating lead asset nizubaglustat in rare disease patients
12/03/2024
Azafaros announces completion of 12-week Phase 2 RAINBOW study evaluating lead asset nizubaglustat in rare disease patients Major milestone reached in bringing new treatment options to patients and their families. [...]
BioSenic releases details of optimized administration approach ahead of planned Phase 3 trial of OATO for chronic graft-versus-host disease
12/03/2024
INSIDE INFORMATION New data builds on earlier findings from a post-hoc Phase 2 analysis that helped reposition BioSenic’s oral arsenic trioxide (OATO) program for pivotal trials. Data to be submitted for peer-reviewed [...]
BioSenic publie les détails de la stratégie d'administration optimisée pour OATO dans le traitement de la maladie chronique du greffon contre l'hôte en amont du prochain essai de phase 3
12/03/2024
INFORMATION PRIVILEGIEE Les nouvelles données s'appuient sur l'analyse post-hoc de résultats antérieurs de phase 2 qui ont permis de repositionner le programme de BioSenic sur le trioxyde d'arsenic oral (OATO) en vue d' [...]
Tecan reports solid underlying sales growth and an increase in profitability and net profit for full year 2023
12/03/2024
Ad hoc announcement pursuant to Article 53 of the SIX Exchange Regulation Listing Rules Tecan reports solid underlying sales growth and an increase in profitability and net profit for full year 2023 Financial results [...]
Belite Bio Announces Availability of Annual Report on Form 20-F Through Company Website
12/03/2024
SAN DIEGO, March 11, 2024 (GLOBE NEWSWIRE) -- Belite Bio, Inc (NASDAQ: BLTE), a clinical-stage biopharmaceutical drug development company focused on advancing novel therapeutics targeting degenerative retinal diseases [...]
Belite Bio Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Update
12/03/2024
Tinlarebant is Belite Bio’s orally administered tablet intended to slow disease progression in patients affected with Stargardt Disease (STGD1) and Geographic Atrophy (GA) in advanced Dry Age-related Macular [...]
Cognition Therapeutics Announces Pricing of $11.5 Million Public Offering of Common Stock
12/03/2024
PURCHASE, N.Y., March 11, 2024 (GLOBE NEWSWIRE) -- Cognition Therapeutics, Inc. (“Cognition,” the “Company” or “We”) (Nasdaq: CGTX), a clinical stage company developing product candidates designed to treat [...]
Assure Holdings Enters into Agreement to Sell Certain of its Assets to MPOWERHealth
11/03/2024
DENVER, March 11, 2024 (GLOBE NEWSWIRE) -- Assure Holdings Corp. (the “Company” or “Assure”) (NASDAQ: IONM), a provider of intraoperative neuromonitoring (“IONM”) and remote neurology services, today announced that it [...]
Foundation Health Secures $6 Million in Seed Funding to Power the Next Generation of Consumer Healthcare Experiences
11/03/2024
Investment Accelerates the Development of SaaS Solutions Suite Featuring API-based Pharmacy and Telehealth Products SAN FRANCISCO, March 11, 2024 (GLOBE NEWSWIRE) -- Foundation Health, a pioneering healthcare technology [...]
Appointment of Dr Darren Patti to Group Chief Operating Officer
11/03/2024
MELBOURNE, Australia, March 12, 2024 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (ASX: TLX, Telix, the Company) is pleased to announce the appointment of Dr. Darren Patti as Group Chief Operating Officer (COO), [...]
Anaptys Announces Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update
11/03/2024
Enrollment ongoing for global Phase 2b trial to treat atopic dermatitis (AD) with ANB032, our BTLA agonist, with top-line data anticipated by year-end 2024 Enrollment ongoing for global Phase 2b trial to treat [...]
BioRestorative Therapies to Participate in the 36th Annual ROTH Conference
11/03/2024
MELVILLE, N.Y., March 11, 2024 (GLOBE NEWSWIRE) -- BioRestorative Therapies, Inc . (“BioRestorative” or the “Company”) (NASDAQ: BRTX ) , a clinical stage company focused on stem cell-based therapies, today announced its [...]
CytomX Therapeutics Reports 2023 Financial Results and Provides Business Update
11/03/2024
- CX-904 (EGFRxCD3 T-cell engager) initial Phase 1a dose escalation data in solid tumors anticipated in the 2nd half of 2024 - - CX-2051 (EpCAM ADC) Phase 1 clinical study initiation in solid tumors, including [...]

Pages